GOSSAMER BIO INC (GOSS)

US38341P1021 - Common Stock

1.18  +0.01 (+0.85%)

After market: 1.18 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

GOSSAMER BIO INC

NASDAQ:GOSS (3/28/2024, 8:13:56 PM)

After market: 1.18 0 (0%)

1.18

+0.01 (+0.85%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap266.18M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

GOSS Daily chart

Company Profile

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California and currently employs 178 full-time employees. The company went IPO on 2019-02-08. The firm is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its product candidates include Seralutinib (GB002), GB5121 and GB7208. GB002 is an inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor in development for the treatment of pulmonary arterial hypertension (PAH). GB5121 is an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK), in clinical development for the treatment of primary central nervous system lymphoma (PCNSL). GB5121 is selected based on its central nervous system, or CNS, penetration and kinase selectivity. GB7208 is an oral, small molecule, BTK inhibitor in preclinical development for the treatment of multiple sclerosis (MS). GB7208 is focused on undergoing preclinical testing.

Company Info

GOSSAMER BIO INC

3013 Science Park Rd

San Diego CALIFORNIA 92121

P: 18589220718

CEO: Faheem Hasnain

Employees: 178

Website: https://www.gossamerbio.com/

GOSS News

News Image17 days ago - Gossamer Bio, Inc.Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
News Image23 days ago - InvestorPlaceGOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023

GOSS stock results show that Gossamer Bio met analyst estimates for earnings per share the fourth quarter of 2023.

News Image23 days ago - BusinessInsiderGOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gossamer Bio (NASDAQ:GOSS) just reported results for the fourth quarter of 2023...

News Image24 days ago - Gossamer Bio, Inc.Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
News Image2 months ago - InvestorPlace7 Micro-Cap Stocks That Could Majorly Surprise Investors

Although extremely small enterprises can be terrifyingly risky, these micro-cap stock surprises deserve a closer look.

News Image3 months ago - Gossamer Bio, Inc.Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GOSS Twits

Here you can normally see the latest stock twits on GOSS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example